In a recent study, it was estimated that more than four million cases are diagnosed annually in the United States alone. Given the widespread prevalence of this disease, there is a substantial impact on overall patient morbidity and quality of life. Similarly, medical treatment for skin cancer accounts for a considerable amount of healthcare expenditures and is often a large financial burden to patients and their families. As such, improved screening and treatment options are imperative to reduce the cost and to refine the outcome of this rising problem.

Read the full article at